Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 12, Bio-Rad Laboratories, Inc. (NYSE:BIO) delivered solid fourth-quarter ...

BIO misses Q4 EPS estimates as margins shrank and shares slid 12%, despite revenue growth and a rebound in Clinical Diagnostics sales.

The global growth factors market is growing steadily, expected to be valued at approximately US$2.5 billion in 2026 and ...

Allied Market Research published a report, titled, "Heart Attack Diagnostics Market by Type (Electrocardiogram, Blood Tests, ...

According to MarketsandMarkets, the Preparative and Process Chromatography Market is projected to grow from about USD 14.32 billion in 2026 ...

The Everstone Capital–backed company, India’s second‑largest home‑grown diversified medtech platform by FY25 operating ...

Bio-Rad develops products and solutions for the life sciences research and clinical diagnostic markets and enjoys niche market leadership in diagnostic quality controls, antigens, and digital ...

Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended ...

Discover the top 4 undervalued Life Sciences Tools & Services stocks for Thursday, February 19 based on AAII’s Stock Grades.

Allied Market Research published a report, titled, "Hydrophobic Interaction Chromatography Market by Product and Service ...

This study reports an important and novel finding that TENT5A, an enzyme involved in fine-tuning poly(A) tail length on selected mRNAs, is required for proper enamel mineralization in mice. The ...